# Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome

Study · id `cardio:ct-nct07799779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07799779](<https://clinicaltrials.gov/study/NCT07799779>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07799779

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 294 participants.

## Technical summary

Registry record NCT07799779. Randomized; single masking; primary purpose treatment. Start 2026-11-30 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 294 participants (planned count; ClinicalTrials.gov record NCT07799779, source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)
- Planned start: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT07799779, source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07799779, source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)
- Completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07799779, source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT07799779, source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07799779-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome
- Acronym: SEsiR-ACS
- Condition: Acute Coronary Syndromes (ACS)
- Intervention (Drug): Inclisiran
- Intervention (Drug): Atorvastatin or Rosuvastatin
- Intervention (Drug): Ezetimibe
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: Dotter Co., Ltd.
- Collaborator class: UNKNOWN
- Collaborator: Novartis Korea Ltd.
- Collaborator class: INDUSTRY
- Collaborator: Hanmi Pharmaceutical co., ltd.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical co., ltd. (`cardio:org-hanmi-pharmaceutical-co-ltd`)

## Provenance

Content hash: 8cd0e11dbe63ce9b164ef13ff55d0eb23fe85176e72b17100c59511d6061d650
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
